貝雅維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價38美元
eyepoint pharmaceuticals分析師評級
H.C. Wainwright維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價30美元
eyepoint pharmaceuticals前景樂觀:DURAVYU在LUGANO三期試驗中提升買入評級
第一資本維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價35美元
加拿大豐業銀行開始對眼點製藥進行覆蓋,並給出板塊表現評級,宣佈目標股價爲18美元
瑞穗證券維持EyePoint Pharmaceuticals(EYPT.US)買入評級
eyepoint pharmaceuticals (EYPT) 從瑞穗證券獲得買入評級
第一資本維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價35美元
eyepoint pharmaceuticals的目標股價由Jefferies宣佈爲15.00美元/分享。
富瑞集團首次給予EyePoint Pharmaceuticals(EYPT.US)買入評級,目標價15美元
在Duravyu有希望的發展中,eyepoint pharmaceuticals的表現優於市場預期。
eyepoint pharmaceuticals 分析師評級
JP摩根維持對eyepoint pharmaceuticals的超配評級,將目標價下調至29美元。
摩根大通維持EyePoint Pharmaceuticals(EYPT.US)買入評級,下調目標價至29美元
分析師就醫療保健公司提供見解:eyepoint pharmaceuticals (EYPT),sarepta therapeutics (SRPT)和intra-cellular therapies (ITCI)
在有希望的DURAVYU試驗前景中,眼點製藥表現出買入樂觀的評級
買入評級得到eyepoint pharmaceuticals強大的財務和有前途的DURAVYU試驗的支撐
Duravyu的療效和安全剖面有所提高,使得甲狀腺藥物eyepoint pharmaceuticals受到買入評級的推崇。
Chardan Capital維持對eyepoint pharmaceuticals的買入評級,維持目標價28美元。